The U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) has recommended the first single-shot COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson, for individuals 18 years of age and older under the Emergency Use Authorization (EUA) issued by the U.S. Food and Drug Administration (FDA). Link
Paul Stoffels, M.D., Vice Chairman of the Executive Committee and Chief Scientific Officer at Johnson & Johnson in a press release on the 28th February announced; “For more than 130 years, Johnson & Johnson has come to the aid of people during times of crisis, and we believe today’s recommendation from the CDC to begin use of our vaccine as part of the U.S. national immunization program will add a critical tool in the fight against COVID-19. This recommendation follows the FDA’s decision to grant an Emergency Use Authorization for our single-shot vaccine, which has the potential to play a pivotal role in helping to end the COVID-19 pandemic.”
The Company’s single-shot COVID-19 vaccine received EUA from the FDA on 27th February, 2021.
The Company has already begun shipping its single-shot vaccine to the U.S. and expects to deliver enough by the end of March to vaccinate more than 20 million people in the U.S. The Company plans to deliver 100 million single-shot vaccines to the U.S. during the first half of 2021
Approval for use of this vaccine is expected in Europe in the near future.
For further information on this vaccine please see our article posted on the 17th February 2021 Link